Figure 3.

Nab-paclitaxel induced in vivo antitumor effects. (A) The spontaneous TAA-induced IH-CCA model was used for drug treatments. All pre-treatment groups of rats exhibited ¹⁸F-FDG-PET-detectable tumors following administration of TAA for 20 weeks. (B) Alterations in SUV 2 and 4 weeks post-treatment with paclitaxel, nab-paclitaxel and gemcitabine/oxaliplatin (G+O), respectively. *P<0.05. TAA, thioacetamide; IH-CCA, intrahepatic cholangiocarcinoma; NS, not significant; SUV, standardized uptake value.